Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $12000.0.

  • Pharmaceuticals' Non Operating Income fell 3333.33% to $12000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $206000.0, marking a year-over-year increase of 14238.68%. This contributed to the annual value of $188000.0 for FY2024, which is 7539.27% down from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' Non Operating Income is $12000.0, which was down 3333.33% from $18000.0 recorded in Q1 2025.
  • Pharmaceuticals' Non Operating Income's 5-year high stood at $1.3 million during Q1 2023, with a 5-year trough of -$1.1 million in Q4 2023.
  • Over the past 4 years, Pharmaceuticals' median Non Operating Income value was $15000.0 (recorded in 2024), while the average stood at $77833.3.
  • The largest annual percentage gain for Pharmaceuticals' Non Operating Income in the last 5 years was 420000.0% (2023), contrasted with its biggest fall of 699375.0% (2023).
  • Quarter analysis of 4 years shows Pharmaceuticals' Non Operating Income stood at -$16000.0 in 2022, then crashed by 6993.75% to -$1.1 million in 2023, then soared by 101.59% to $18000.0 in 2024, then crashed by 33.33% to $12000.0 in 2025.
  • Its Non Operating Income was $12000.0 in Q2 2025, compared to $18000.0 in Q1 2025 and $18000.0 in Q2 2024.